Related Experiment Video
Updated: Sep 24, 2025
Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
Published on: February 12, 2017
Application of Anlotinib Combined With Neoadjuvant Chemotherapy in Primary EWS/PNET of Lung: A Case Report
1Department of Thoracic Surgery, Shanxi Province Cancer Hospital/Shanxi Hospital Affiliated to Cancer Hospital, Chinese Academy of Medical Sciences/Cancer Hospital Affiliated to Shanxi Medical University, Taiyuan, China.
Abstract:
Primary pulmonary EWS/PNET(PPES) is extremely rare and is associated with a poor prognosis. Tumor angiogenesis plays an important role in tumor, so it has become a hot topic in molecular targeted therapy. Anlotinib is a new oral small molecular multi-targeted receptor tyrosine kinase (RTK) inhibitor. This report describes a 20 year-old man with PPES. After 4 neoadjuvant chemotherapy cycles (VACwith alternating IE) combined with anlotinib, the left total pneumonectomy was performed. Then maintenance anlotinib monotherapy was continued, no sign of recurrence to date as an outcome. To our knowledge, this is the first demonstration of anlotinib combined with neoadjuvant chemotherapy efficacy in PPES.
Insights
This study reports a novel treatment for primary pulmonary Ewing sarcoma/primitive neuroectodermal tumors (PPES). Combining anlotinib with chemotherapy showed efficacy in a young patient, with no recurrence observed post-surgery.
Area of Science:
- Oncology
- Molecular Targeted Therapy
- Surgical Oncology
Background:
- Primary pulmonary Ewing sarcoma/primitive neuroectodermal tumors (PPES) are exceptionally rare and carry a poor prognosis.
- Tumor angiogenesis is a critical factor in tumor progression and a target for molecular therapies.
- Anlotinib is an oral, multi-targeted receptor tyrosine kinase (RTK) inhibitor.
Observation:
- A 20-year-old male patient diagnosed with PPES was treated with neoadjuvant chemotherapy (VAC alternating with IE) and anlotinib.
- The patient underwent a left total pneumonectomy after four cycles of treatment.
Findings:
- Anlotinib, a multi-targeted receptor tyrosine kinase inhibitor, was administered concurrently with chemotherapy.
- Following surgery, maintenance anlotinib monotherapy was given, resulting in no signs of recurrence to date.
Implications:
- This case represents the first documented efficacy of anlotinib combined with neoadjuvant chemotherapy for PPES.
- The findings suggest a potential new therapeutic strategy for this rare and challenging cancer.
